Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents

被引：0
|
作者：
Jumpei Teramachi
Hirokazu Miki
Shingen Nakamura
Masahiro Hiasa
Takeshi Harada
Masahiro Abe
机构：
[1] Tokushima University Graduate School of Biomedical Sciences,Department of Hematology, Endocrinology and Metabolism
[2] Okayama University Graduate School,Department of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences
[3] Tokushima University Hospital,Division of Transfusion Medicine and Cell Therapy
[4] Tokushima University Graduate School of Biomedical Sciences,Department of Community Medicine and Medical Science
[5] Tokushima University Graduate School of Biomedical Sciences,Department of Orthodontics and Dentofacial Orthopedics
来源：
Journal of Bone and Mineral Metabolism | 2023年 / 41卷
关键词：
Myeloma bone disease; Receptor activator of nuclear factor-κB ligand; Bone-modifying agents; Proteasome inhibitors; Daratumumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：388 / 403
页数：15
相关论文
共 50 条
  • [1] Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents
    Teramachi, Jumpei
    Miki, Hirokazu
    Nakamura, Shingen
    Hiasa, Masahiro
    Harada, Takeshi
    Abe, Masahiro
    JOURNAL OF BONE AND MINERAL METABOLISM, 2023, 41 (03) : 388 - 403
  • [2] Novel Anti-Myeloma Agents and Bone Metabolism: Implications in the Management of Myeloma Bone Disease
    Terpos, Evangelos
    Christoulas, Dimitrios
    Kastritis, Efstathios
    Migkou, Magda
    Gavriatopoulou, Maria
    Dimopoulos, Meletios-Athanassios
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S30 - S32
  • [3] The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    E Terpos
    M-A Dimopoulos
    O Sezer
    Leukemia, 2007, 21 : 1875 - 1884
  • [4] The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    Terpos, E.
    Dimopoulos, M-A
    Sezer, O.
    LEUKEMIA, 2007, 21 (09) : 1875 - 1884
  • [5] Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Gavriatopoulou, Maria
    Kalapanida, Despoina
    Eleutherakis-Papaiakovou, Evangelos
    Roussou, Maria
    Mparmparoussi, Despoina
    Zomas, Athanasios
    Gika, Dimitra
    Kartasis, Zafiris
    Matsouka, Charis
    Kostis, Evangelos
    Kontogiannis, Sofoklis
    Konstantopoulos, Kostas
    Kastritis, Efstathios
    BLOOD, 2014, 124 (21)
  • [6] Pathogenesis and management of myeloma bone disease
    Christoulas, Dimitrios
    Terpos, Evangelos
    Dimopoulos, Meletios A.
    EXPERT REVIEW OF HEMATOLOGY, 2009, 2 (04) : 385 - 398
  • [7] Novel anti-myeloma agents and angiogenesis
    Anargyrou, Konstantinos
    Dimopoulos, Meletios-Athanassios
    Sezer, Orhan
    Terpos, Evangelos
    LEUKEMIA & LYMPHOMA, 2008, 49 (04) : 677 - 689
  • [8] Avicins: A novel class of anti-myeloma agents
    Negri, J.
    Mitsiades, N.
    McMullan, C. J.
    Hayden, P.
    McMillin, D.
    Klippel, S.
    Tesmenitsky, Y.
    Haridas, V.
    Munshi, N.
    Richardson, P.
    Gutterman, J.
    Anderson, K. C.
    Mitsiades, C. S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 144 - 144
  • [9] Modulation of cereblon levels by anti-myeloma agents
    Diaz-Rodriguez, Elena
    Pandiella, Atanasio
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 167 - 176
  • [10] Avicins: A novel class of anti-myeloma agents.
    Mitsiades, N
    McMullan, CJ
    Poulabi, V
    Negri, J
    Geer, DC
    Haridas, V
    Munshi, NC
    Gutterman, J
    Anderson, KC
    Mitsiades, CS
    BLOOD, 2004, 104 (11) : 929A - 929A
12345